|
93
|
324
|
8hv9A |
Crystal structure of egfr_tmx in complex with covalently bound fragment 12 |
|
91
|
324
|
8hv7A |
Crystal structure of egfr_tmx in complex with covalently bound fragment 9 |
|
97
|
325
|
8hvaA |
Crystal structure of egfr_tmx in complex with covalently bound compound 14 |
|
97
|
324
|
8hv5A |
Crystal structure of egfr_dmx in complex with compound 7 |
|
93
|
325
|
8hv6A |
Crystal structure of egfr_tmx in complex with covalently bound fragment 8 |
|
95
|
323
|
8hv2A |
Crystal structure of egfr_wt in complex with covalently bound fragment 4 |
|
95
|
325
|
8hv4A |
Crystal structure of egfr_tmx in complex with covalently bound fragment 4 |
|
95
|
324
|
8hv1A |
Crystal structure of egfr_dmx in complex with covalently bound fragment 1 |
|
97
|
325
|
8hv3A |
Crystal structure of egfr_dmx in complex with covalently bound fragment 4 |
|
91
|
322
|
7kxzA |
Active conformation of egfr kinase in complex with bi-4020 |
|
81
|
307
|
7ky0A |
Inactive conformation of egfr (t790m/v948r) kinase in complex with bi-4020 |
|
78
|
305
|
7lg8A |
Egfr (t79m/v948r) in complex with naquotinib and an allosteric inhibitor |
|
86
|
301
|
7f3mA |
Crystal structure of fgfr4 kinase domain with prn1371 |
|
89
|
298
|
7du9A |
Crystal structure of human proto-oncogene tyrosine-protein kinase receptor ret in complex with pralsetinib |
|
92
|
299
|
7du8A |
Crystal structure of human proto-oncogene tyrosine-protein kinase receptor ret in complex with selpercatinib |
|
97
|
300
|
7duaA |
Crystal structure of human proto-oncogene tyrosine-protein kinase receptor ret in complex with 4-amino-7-(1-methylcyclopropyl)-n-(5-methyl-1h-pyrazol-3-yl)pyrrolo[2,3-d]pyrimidine-5-carboxamide |
|
91
|
324
|
7b85A |
Crystal structure of egfr-wt in complex with tak-788 |
|
80
|
284
|
7a6jA |
Crystal structure of egfr-t790m/v948r in complex with poziotinib |
|
83
|
282
|
7a6iA |
Crystal structure of egfr-t790m/v948r in complex with ldc8201 |
|
75
|
285
|
7a6kA |
Crystal structure of egfr-t790m/v948r in complex with tak-788 |
|
82
|
284
|
8bocA |
Crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 19 |
|
93
|
323
|
7vraA |
The crystal structure of egfr t790m/c797s with the inhibitor hc5476 |
|
97
|
323
|
7vreA |
The crystal structure of egfr t790m/c797s with the inhibitor hcd2892 |
|
88
|
922
|
7s8vB |
Leg region of a complex of igf-i with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
94
|
309
|
7r7rA |
Structure of human anaplastic lymphoma kinase domain in complex with ((2~{r})-2-[5-[6-amino-5-[(1~{r})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol) |
|
56
|
411
|
7s0qB |
Head region of a complex of igf-i with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
41
|
320
|
7s8vA |
Leg region of a complex of igf-i with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
91
|
577
|
7s0qA |
Head region of a complex of igf-i with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
97
|
307
|
7r7kA |
Structure of human anaplastic lymphoma kinase domain in complex with (4-[6-amino-5-[(1~{r})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]isoindolin-1-one) |
|
19
|
125
|
7n1jA |
Crystal structure of fgfr4 domain 3 in complex with a de novo-designed mini-binder |
|
83
|
348
|
7n3tA |
Trka ecd complex with designed miniprotein ligand |
|
87
|
304
|
5sb2A |
Ddr1, 3-chloro-n-[(1r,2s)-2-phenylcyclopropyl]-5-(1h-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.600a, p212121, rfree=23.2% |
|
92
|
307
|
5saxA |
Ddr1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-n-[3-(trifluoromethyl)phenyl]acetamide, 1.902a, second p212121 form, rfree=25.4%, second form |
|
79
|
316
|
7ctvA |
Crystal structure of arabidopsis thaliana sobir1 kinase domain d489a mutant in complex with amp-pnp and magnesium |
|
93
|
322
|
7er2A |
Crystal structure of egfr 696-1022 t790m/c797s in complex with ls_2_40 |
|
94
|
299
|
5sawA |
Ddr1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-n-[3-(trifluoromethyl)phenyl]acetamide, 1.601a, p212121, rfree=22.6% |
|
89
|
303
|
5sauA |
Ddr1, 3-[2-(6-aminopyridin-3-yl)ethynyl]-n-[3-(trifluoromethyl)phenyl]benzamide, 1.800a, p212121, rfree=23.1% |
|
99
|
302
|
5savA |
Ddr1, n-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 1.760a, p212121, rfree=23.5% |
|
89
|
304
|
5sb1A |
Ddr1, 4-chloro-n-[(3s,4r)-4-phenylpyrrolidin-3-yl]-3-(1h-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.530a, p212121, rfree=21.4% |
|
78
|
303
|
7ctxA |
Crystal structure of arabidopsis thaliana sobir1 kinase domain(residues 388-401 deleted) in complex with amp-pnp and magnesium |
|
89
|
300
|
5sayA |
Ddr1, n-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 2.190a, p1211, rfree=27.7% |
|
96
|
305
|
5sazA |
Ddr1, 3-chloro-n-[4-chloro-3-(1h-pyrrolo[2,3-b]pyridin-5-ylcarbamoyl)phenyl]-4-(2-hydroxyethylamino)benzamide, 1.802a, p212121, rfree=22.2% |
|
90
|
304
|
5sb0A |
Ddr1, n-[[2-(2-pyridin-3-yloxyethyl)cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide, 1.970a, p212121, rfree=25.6% |
|
87
|
298
|
8au3A |
C-met y1234e,y1235e mutant in complex with tepotinib |
|
73
|
280
|
8au5A |
C-met f1200i mutant in complex with tepotinib |
|
80
|
280
|
8aw1A |
C-met y1235d mutant in complex with tepotinib |
|
82
|
288
|
8ow3A |
Crystal structure of wild-type c-met bound by compound 2 |
|
87
|
285
|
8pyjAAA |
Human igf1r with inhibitor 8 |
|
89
|
285
|
8pynAAA |
Human igf1r with inhibitor 56 |
|
88
|
301
|
8pyiAAA |
Human igf1r with inhibitor 6 |
